Comparison of Angiotensin Converting Enzyme Inhibitors and Beta Blockers in Prevention of Atrial Fibrillation Recurrences After Electrical Cardioversion Elektriksel Kardiyoversiyon Sonrasında Atriyal

Year 2007, Volume: 60 Issue: 4, 158 - 163, 01.04.2007

Timuçin Altın Adalet Gürlek Çağdaş Özdöl Mustafa Kılıçkap İrem Dinçer Sibel Turhan Çetin Erol

https://doi.org/10.1501/Tipfak_0000000570

https://izlik.org/JA42NA93HA

Abstract

Keywords

-

Elektriksel Kardiyoversiyon Sonrasında Atriyal Fibrilasyon Nükslerinin Önlenmesinde Anjiyotensin Dönüştürücü Enzim İnhibitörleri ve Beta Blokerlerin Karşılaştırılması

https://izlik.org/JA42NA93HA

Abstract

Amaç: Atriyal fi brilasyonun (AF) elektriksel kardiyoversiyonu sonrasında, anjiyotensin dönüştürücü enzim (ACE) inhibitörleri ve beta blokerlerin atriyal yapısal ve elektriksel remodeling’ i azaltmak suretiyle AF nükslerini azalttığı gösterilmiştir. Bu çalışmada, kardiyoversiyon sonrasında ACE inhibitörü cilazapril ve beta bloker metoprolol’ ün sinüs ritmi idamesindeki etkileri karşılaştırıldı. Hastalar ve Yöntem: Çalışmaya persistan AF’si olup başarılı kardiyoversiyon yapılan 120 hasta alındı. Kardiyoversiyon sonrasında hastalar 3 gruba randomize edildi. Grup I’ e (n=41) amiodaron, Grup II’ ye (n=41) amiodaron+metoprolol, Grup III’ e (n=38) amiodaron+cilazapril verildi. Çalışmanın primer sonlanım noktası AF nüks oranları ve AF nüksü görülenlerde nükse kadar geçen zaman idi. Bulgular: Bir yıllık takip sonunda gruplar arasında sinüs ritmi idamesi arasında anlamlı fark saptanmadı (Kaplan Meier analizi, sırasıyla %24, %37 and %26; log rank=0.3). AF nüks zamanları açısından da gruplar arasında fark gözlenmedi. Sonuç: Amiodaron, amiodaron+metoprolol veya amiodaron+cilazapril tedavilerinin AF nüksü üzerine etkileri benzer bulunmuştur

Keywords

Atriyal fi brilasyon , kardiyoversiyon , anjiyotensin dönüştürücü enzim inhibitörleri , beta blokerler

References

• Birnie DH, Gollob M, Healey JS. Clini- cal trials, the renin angiotensin system and atrial fibrillation. Curr Opin Cardiol 2006;21:368-375.
• Van Gelder IC, Crijns HJ, Van Gilst WH, et al. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation or atrial flutter. Am J Cardiol 1991;68:41-46.
• Shiroshita-Takeshita A, Brundel BJJM, Nat- tel S. Atrial fibrillation: Basic mechanisms, remodeling and triggers. J Interv Card Electr 2005;13:181-193.
• Mehta PK, Griendling KK. Angiotensin II cell signalling: Physiological and patholo- gical effects in the cardiovascular system. Am J Physiol Cell Physiol 2007;292:C82- 97.
• Goette A, Staack T, Röcken C, et al. Incre- ased expression of extracellular signal-re- gulated kinase and angiotensin-converting enzyme in human atria during atrial fibril- lation. J Am Coll Cardiol 2000;35:1669- 1677.
• Li D, Shinagawa K, Pang L, et al. Effects of angiotensin-converting enzyme inhibi- tion on the development of the atrial fib- rillation substrate in dogs with ventricular tachypacing-induced congestive heart fai- lure. Circulation 2001;104:2608-2614.
• Nakashima H, Kumagai K, Urata H, et al. Angiotensin II antagonist prevents electri- cal remodelling in atrial fibrillation. Cir- culation 2000;101:2612-2617.
• Ueng KC, Tsai TP, Yu WC, et al. Use of enalapril to facilitate sinus rhythm main- tenance after external cardioversion of long-standing persistent atrial fibrillation. Eur Heart J 2003;24:2090-2098.
• Madrid AH, Bueno MG, Rebollo JMG, 17. Cardin S, Li D, Thorin-Trescases N, et al. et al. Use of irbesartan to maintain si- nus rhythm in patients with long-lasting persistent atrial fibrillation. Circulation 2002;106:331-336.
• Lombardi F, Colombo A, Basilico B, et al. Heart rate variability and early recurrence of atrial fibrillation after electrical cardio- version. J Am Coll Cardiol 2001;37:157- 162.
• Tieleman RG, Van Gelder IC, Crijns HJGM, et al. Early recurrences of atrial fibrillation after electrical cardioversion: A result of fibrillation-induced electrical remodeling of the atria? J Am Coll Cardiol 1998;31:167-173.
• Kühlkamp V, Schirdewan A, Stangl K, et al. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from per- sistent atrial fibrillation. A randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2000;36:139-146.
• Plewan A, Lehmann G, Ndrepepa G, et al. Maintenance of sinus rhythm after electri- cal cardioversion of persistent atrial fibril- lation. Eur Heart J 2001;22:1504-1510.
• Kalus JS, Coleman CI, White CM. The im- pact of supressing the renin-angiotensin system on atrial fibrillation. J Clin Phar- macol 2006;46:21-28.
• Shinagawa K, Mitamura H, Ogawa S, et al. Effects of inhibiting Na+ /H+ - Exchange or angiotensin converting enzyme on at- rial tchycardia-induced remodeling. Car- diovasc Res 2002;54:438-446.
• Li Y, Li W, Gong Y, et al. The effects of ci- lazapril and valsartan on the mRNA and expressions of atrial calpains and atrial structural remodeling in atrial fibrillation in dogs. Basic Res Cardiol 2007; Feb 2 (Epub ahead of print). Evolution of the atrial fibrllation substrate in experimental congestive heart failure: Angiotensin-dependent and -independent pathways. Cardiovasc Res 2003;60:315- 325.
• Van Noord T, Tieleman RG, Bosker HA, et al. Beta-blockers prevent subacute recur- rences of persistent atrial fibrillation only in patients with hypertension. Europace 2004;6:343-350.
• Workman AJ, Kane KA, Russell JA, et al. Chronic beta-adrenoceptor blockade and human atrial cell electrophysiology: evi- dence of pharmacological remodeling. Cardiovasc Res 2003;58:518-525.
• Wachtell K, Lehto M, Gerdts E, et al. An- giotensin II receptor blockade reduces new-onset atrial fibrillation and subsequ- ent stroke compared to atenolol. The losartan intervention for end-point redu- ction in hypertension (LIFE) study. J Am Coll Cardiol 2005;45:712-719.
• Schmieder K, Sclaich MP, Klingbeil AU, et al. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized doub- le-blind studies until December 1996). Nephrol Dial Transplant 1998;13:564- 569.
• Hansson L, Lindholm LH, Ekborn T, et al. Randomised trial of old and new antihy- pertensive drugs in elderly patients: car- diovascular mortality and morbidity the Swedish trial in Old Patients with Hyper- tension-2 study. Lancet 1999;354:1751- 1756.
• Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzy- me inhibition compared with conventio- nal therapy on cardiovascular morbidity and mortality in hypertension: the Cap- topril Prevention Project (CAPPP) rando- mised trial. Lancet 1999;353:611-616.
• Ehrlich JR, Hohnloser SH, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J 2006;27:512-518.
• Healey JS, Morillo CA, Connolly SJ. Role of the renin-angiotensin-aldosterone sys- tem in atrial fibrillation and cardiac remo- deling. Curr Opin Cardiol 2004;20:31-37.
• Boldt A, Scholl A, Garbade J, et al. ACE- inhibitor treatment attenuates atrial struc- tural remodeling in patients with lone ch- ronic atrial fibrillation. Basic Res Cardiol 2006;101:261-267.